Elanco Animal Health (NYSE:ELAN) Issues FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.030-1.090 for the period, compared to the consensus EPS estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.1 billion, compared to the consensus revenue estimate of $5.0 billion. Elanco Animal Health also updated its Q2 2026 guidance to 0.250-0.285 EPS.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ELAN. Citigroup began coverage on Elanco Animal Health in a research report on Wednesday, April 15th. They issued a “buy” rating and a $30.00 price objective for the company. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, KeyCorp lifted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.90.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $23.05 on Wednesday. The firm has a market capitalization of $11.46 billion, a PE ratio of -48.02, a P/E/G ratio of 2.87 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The business has a 50-day moving average of $23.82 and a two-hundred day moving average of $23.29. Elanco Animal Health has a 12 month low of $9.42 and a 12 month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts forecast that Elanco Animal Health will post 1.03 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Compound Planning Inc. boosted its position in shares of Elanco Animal Health by 29.7% in the fourth quarter. Compound Planning Inc. now owns 21,312 shares of the company’s stock worth $482,000 after buying an additional 4,876 shares during the period. Invesco Ltd. boosted its holdings in Elanco Animal Health by 336.0% in the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after purchasing an additional 3,690,735 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Elanco Animal Health by 122.3% in the fourth quarter. Corient Private Wealth LLC now owns 165,381 shares of the company’s stock valued at $3,743,000 after purchasing an additional 90,993 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Elanco Animal Health by 29.0% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 78,610 shares of the company’s stock valued at $1,779,000 after purchasing an additional 17,657 shares during the last quarter. Finally, State of Tennessee Department of Treasury boosted its holdings in Elanco Animal Health by 8.1% in the fourth quarter. State of Tennessee Department of Treasury now owns 146,658 shares of the company’s stock valued at $3,532,000 after purchasing an additional 11,012 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.